Black Diamond Therapeutics (BDTX)
(Delayed Data from NSDQ)
$6.23 USD
+0.15 (2.47%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $6.24 +0.01 (0.16%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Brokerage Reports
Black Diamond Therapeutics, Inc. [BDTX]
Reports for Purchase
Showing records 21 - 40 ( 90 total )
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology- 2023 Small Molecule Precision Oncology Review and Outlook
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
BDTX-1535 Dose Escalation NSCLC Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
EORTC-NCI-AACR 2023: Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology- EORTC-NCI-AACR 2023 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
BDTX-1535 Forges Ahead; Landscape Updates at WCLC
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Q2 Financials; BDTX-1535 NSCLC Data Impresses; GBM Ph1 Data Up Next
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Highly Encouraging Initial NSCLC Results for BDTX-1535; Upgrading to Buy and $11 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Upgrading to OUTPERFORM with a $10 PT; A Diamond Emerges from the Rough
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Q1 Financials; Is BDTX-1535 a Diamond in the Rough?
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
ASCO 2023 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology- Roundup for 2023 AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology - Roundup For 2023 AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology -AACR 2023 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Still in Holding Pattern; 2022 Financial Results; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Q4 Financials; Ph 1 BDTX-1535 Data on Track for 2H:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R